drugset / Trial / NCT07043322

Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

NCT07043322

Phase 2 Recruiting 150 enrolled Tanta University
RandomizedParallel-groupDouble-blindTreatment

Summary

Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of controlled ovarian stimulation of gonadotrophin-Stimulated ovarian cycles. It is theorized to manifest systemically as a result of vasoactive mediators like vascular endothelium growth factor (VEGF) being released from hyperstimulated ovaries. As a result, capillary permeability is increased which causes the extravasation of fluid from the intravascular compartment into the third space. The haemoconcentration which ensues results in complications such as hypercoagulability and reduced end organ perfusion.

Timeline

Start
2025-06-30
Primary completion
2026-10-20
Completion
2026-11-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cabergoline Small molecule 0.25 mg